Paola Menichini

Dr. Paola Menichini

IRCCS Ospedale Policlinico San Martino
orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1991 in Nucleic Acids Research
Verified
Journal Article
Closed access
HVHarry Vrieling
Harry Vrieling
JVJaap Venema
Jaap Venema
MRMarie-Louise van Rooyen
Marie-Louise van Rooyen
AHAnneke van Hoffen
Anneke van Hoffen
PMPaola Menichini
Paola Menichini
AZAlbert A. van Zeeland
Albert A. van Zeeland
DNA excision repair modulates the mutagenic effect of many genotoxic agents. The recently observed strand specificity for removal of UV-induced cyclobutane dimers from actively transcribed genes in mammalian cells could influence the nature and distribution of mutations in a particular gene. To investigate this, we have analyzed UV-induced DNA repair and mutagenesis in the same gene, i.e. the hypoxanthine phosphoribosyl-transferase (hprt) gene. In 23 hprt mutants from V79 Chinese hamster cells induced by 2 J/m2 UV we found a strong strand bias for mutation induction: assuming that pre-mutagenic lesions occur at dipyrimidine sequences, 85% of the mutations could be attributed to lesions in the nontranscribed strand. Analysis of DNA repair in the hprt gene revealed that more than 90% of the cyclobutane dimers were removed from the transcribed strand within 8 hours after irradiation with 10 J/m2 UV, whereas virtually no dimer removal could be detected from the nontranscribed strand even up to 24 hr after UV. These data present the first proof that strand specific repair of DNA lesions in an expressed mammalian gene is associated with a strand specificity for mutation induction.

15 March 2011 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
PMPaola Monti
Paola Monti
CPChiara Perfumo
Chiara Perfumo
ABAlessandra BISIO
Alessandra BISIO
Yari CiribilliYari Ciribilli
Yari Ciribilli
PMPaola Menichini
Paola Menichini
GFGilberto Fronza
Gilberto Fronza
Germline TP53 mutations result in cancer proneness syndromes known as Li-Fraumeni, Li-Fraumeni-like, and nonsyndromic predisposition with or without family history. To explore genotype/phenotype associations, we previously adopted a functional classification of all germline TP53 mutant alleles based on transactivation. Severe deficiency (SD) alleles were associated with more severe cancer proneness syndromes, and a larger number of tumors, compared with partial deficiency (PD) alleles. Because mutant p53 can exert dominant-negative (DN) effects, we addressed the relationship between DN and clinical manifestations. We reasoned that DN effects might be stronger in familial cancer cases associated with germline TP53 mutations, where mutant alleles coexist with the wild-type allele since conception. We examined 104 p53 mutant alleles with single amino acid substitutions described in the IARC germline database for (i) transactivation capability and (ii) capacity to reduce the activity of the wild-type allele (i.e., DN effect) using a quantitative yeast-based assay. The functional classifications of p53 alleles were then related to clinical variables. We confirmed that a classification based on transactivation alone can identify familial cancer cases with more severe clinical features. Classification based on DN effects allowed us to highlight similar associations but did not reveal distinct clinical subclasses of SD alleles, except for a correlation with tumor tissue prevalence. We conclude that in carriers of germline TP53 mutations transactivation-based classification of TP53 alleles appears more important for genotype/phenotype correlations than DN effects and that haplo-insufficiency of the TP53 gene is an important factor in cancer proneness in humans. Mol Cancer Res; 9(3); 271–9. ©2011 AACR.

28 September 2006 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
ACA. Catassi
A. Catassi
Alfredo CesarioAlfredo Cesario
Alfredo Cesario
DAD. Arzani
D. Arzani
PMPaola Menichini
Paola Menichini
AAAngela Alama
Angela Alama
PRP. Russo
P. Russo

1 July 2007 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
PMPaola Monti
Paola Monti
Yari CiribilliYari Ciribilli
Yari Ciribilli
JJJennifer Jordan
Jennifer Jordan
PMPaola Menichini
Paola Menichini
DUDavid M. Umbach
David M. Umbach
GFGilberto Fronza
Gilberto Fronza
Purpose: The TP53 tumor suppressor gene encodes a sequence-specific transcription factor that is able to transactivate several sets of genes, the promoters of which include appropriate response elements. Although human cancers frequently contain mutated p53, the alleles as well as the clinical expression are often heterogeneous. Germ line mutations of TP53 result in cancer proneness syndromes known as Li-Fraumeni, Li-Fraumeni–like, and nonsyndromic predisposition with or without family history. p53 mutants can be classified as partial deficiency alleles or severe deficiency alleles depending on their ability to transactivate a set of human target sequences, as measured using a standardized yeast-based assay (see http://www.umd.be:2072/index.html). We have investigated the extent to which the functional features of p53 mutant alleles determine clinical features in patients who have inherited these alleles and have developed cancer. Experimental Design: We retrieved clinical data from the IARC database (see http://www.p53.iarc.fr/Germline.html) for all cancer patients with germ line p53 mutations and applied stringent statistical evaluations to compare the functional classification of p53 alleles with clinical phenotypes. Results: Our analyses reveal that partial deficiency alleles are associated with a milder family history (P = 0.007), a lower numbers of tumors (P = 0.007), and a delayed disease onset (median, 31 versus 15 years; P = 0.007) which could be related to distinct tumor spectra. Conclusions: These findings establish for the first time significant correlations between the residual transactivation function of individual TP53 alleles and clinical variables in patients with inherited p53 mutations who develop cancer.

19 February 2019 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
GFGiorgia Foggetti
Giorgia Foggetti
LOLaura Ottaggio
Laura Ottaggio
DRDebora Russo
Debora Russo
Carlotta MazzitelliCarlotta Mazzitelli
Carlotta Mazzitelli
PMPaola Monti
Paola Monti
PMPaola Menichini
Paola Menichini
Missense mutations in the TP53 gene produce mutant p53 (mutp53) proteins which may acquire oncogenic properties favoring chemoresistance, cell migration, and metastasis. The exploitation of cellular pathways that promote mutp53 degradation may reduce cell proliferation and invasion as well as increase the sensitivity to anticancer drugs, with a strong impact on current cancer therapies. In the last years, several molecules have been characterized for their ability to induce the degradation of mutp53 through the activation of autophagy. Here, we investigated the correlation between autophagy and mutp53 degradation induced by suberoylanilide hydroxamic acid (SAHA), an FDA-approved histone deacetylase inhibitor. In the human cancer lines MDA-MB-231 (mutp53-R280K) and DLD1 (mutp53-S241F), SAHA induced a significant mutp53 degradation. However, such degradation correlated with autophagy induction only in MDA-MB-231 cells, being counteracted by autophagy inhibition, which also increased SAHA-induced cell death. Conversely, in DLD1 cells SAHA triggered a low level of autophagy despite promoting a strong decrease in mutp53 level, and autophagy inhibition did not change either mutp53 levels or sensitivity to this drug. We conclude that autophagy can be a relevant pathway for mutp53 degradation induced by SAHA, but its contribution to mutp53 destabilization and the consequences on cell death are likely context-dependent.

1 November 1991 in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
Verified
Journal Article
Closed access
PMPaola Menichini
Paola Menichini
HVHarry Vrieling
Harry Vrieling
AZA.A. van Zeeland
A.A. van Zeeland